Evogene Ltd. (NASDAQ:EVGN) traded sharply higher on Thursday after the company posted third-quarter results that topped profit expectations, even as revenue came in well below forecasts.
Shares of the computational chemistry and AI-driven small-molecule design firm rose 5.13% in premarket trading following the announcement.
For the quarter, Evogene reported a net loss of $0.31 per share, significantly better than analysts’ projected loss of $0.43. Revenue, however, totaled $310,000, missing estimates of $575,000 and falling sharply from $1.7 million a year ago. The company attributed the drop mainly to lower seed sales at its Casterra unit.
Evogene’s ongoing shift toward becoming a pure-play leader in computational chemistry—centered on generative small-molecule design for both pharma and agriculture—has begun to yield meaningful cost benefits. A cost-cutting program, largely completed by late Q2, reduced quarterly operating expenses to $2.9 million, compared with $6.6 million in the same period of 2024.
“Evogene is at a turning point – becoming a focused, AI-driven company built around our core engine, ChemPass AI,” said Mr. Ofer Haviv, President & CEO of Evogene. “This cutting-edge platform is redefining how small molecules are discovered and optimized, driving innovation across two global industries: pharma and agriculture.”
The company closed the quarter with roughly $16 million in cash and short-term deposits. That figure includes proceeds from its sale of Lavie Bio’s assets and the MicroBoost AI for Ag technology engine to ICL—transactions that contributed about $7.9 million in income during Q3.
For the first nine months of 2025, Evogene reported an operating loss of approximately $8.8 million, a sharp improvement from $15.3 million in the comparable period of 2024, largely reflecting lower expenses across its subsidiaries.